JP2019523266A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523266A5
JP2019523266A5 JP2019503928A JP2019503928A JP2019523266A5 JP 2019523266 A5 JP2019523266 A5 JP 2019523266A5 JP 2019503928 A JP2019503928 A JP 2019503928A JP 2019503928 A JP2019503928 A JP 2019503928A JP 2019523266 A5 JP2019523266 A5 JP 2019523266A5
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
phenyl
oxo
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503928A
Other languages
English (en)
Japanese (ja)
Other versions
JP6986065B2 (ja
JP2019523266A (ja
Filing date
Publication date
Priority claimed from GBGB1612938.9A external-priority patent/GB201612938D0/en
Application filed filed Critical
Publication of JP2019523266A publication Critical patent/JP2019523266A/ja
Publication of JP2019523266A5 publication Critical patent/JP2019523266A5/ja
Application granted granted Critical
Publication of JP6986065B2 publication Critical patent/JP6986065B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503928A 2016-07-26 2017-07-26 医薬化合物 Active JP6986065B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612938.9A GB201612938D0 (en) 2016-07-26 2016-07-26 Pharmaceutical compounds
GB1612938.9 2016-07-26
PCT/GB2017/052178 WO2018020242A1 (en) 2016-07-26 2017-07-26 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
JP2019523266A JP2019523266A (ja) 2019-08-22
JP2019523266A5 true JP2019523266A5 (enExample) 2020-09-03
JP6986065B2 JP6986065B2 (ja) 2021-12-22

Family

ID=56894331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503928A Active JP6986065B2 (ja) 2016-07-26 2017-07-26 医薬化合物

Country Status (15)

Country Link
US (2) US11053213B2 (enExample)
EP (1) EP3490982B1 (enExample)
JP (1) JP6986065B2 (enExample)
KR (1) KR20190034564A (enExample)
CN (1) CN109790146B (enExample)
AU (1) AU2017304761C1 (enExample)
BR (1) BR112019001253A2 (enExample)
CA (1) CA3031036A1 (enExample)
ES (1) ES2914677T3 (enExample)
GB (1) GB201612938D0 (enExample)
IL (1) IL264415B (enExample)
MX (1) MX382624B (enExample)
SG (1) SG11201900545TA (enExample)
WO (1) WO2018020242A1 (enExample)
ZA (1) ZA201900540B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
US11465983B2 (en) 2017-09-26 2022-10-11 Dana-Farber Cancer Institute, Inc. USP7 inhibitors for treating multiple myeloma
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
JP7508449B2 (ja) 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Usp7の阻害
CN113365696A (zh) * 2018-12-06 2021-09-07 阿尔麦克探索有限公司 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途
BR112021010645A2 (pt) * 2018-12-06 2021-08-17 Almac Discovery Limited composto, 1-(((s)-7-((r)-3-ciclohexil-2-metilpropanoil)-10-hidroxi-7-azaspiro[4.5]decan-10-il)metil)-4-fenil-5-(piperazina-1-carbonila)piridin-2(1h)-ona, composição farmacêutica, métodos para tratamento de obesidade, de resistência à insulina, de diabetes tipo ii, de atrofia muscular, de câncer e para reduzir perda de massa muscular, e, inibidor de usp19
WO2020227365A1 (en) 2019-05-06 2020-11-12 Integral Early Discovery, Inc. Inhibiting usp19
MX2022005819A (es) * 2019-11-13 2022-08-16 Univ Temple Nuevas lactonas funcionalizadas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso.
CN111039860B (zh) * 2019-12-02 2022-09-13 河北科技大学 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用
GB202001980D0 (en) * 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
USD991067S1 (en) 2020-10-17 2023-07-04 Honeywell International Inc. Modular aspirated smoke, gas, and air quality monitoring system device
GB202104097D0 (en) 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003501428A (ja) 1999-06-02 2003-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロリジニル、ピペリジニルもしくはホモピペリジニル置換(ベンゾジオキサン、ベンゾフランもしくはベンゾピラン)誘導体
EP2552013A1 (en) * 2011-07-27 2013-01-30 Siemens Aktiengesellschaft Reduction of noise and vibrations of an electromechanical transducer by using a modified stator coil drive signal comprising harmonic components
GB201114448D0 (en) * 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
JP6535007B2 (ja) 2013-12-20 2019-06-26 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ 新規ピペリジンカルボキサミド化合物、その調製方法及び使用
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
HRP20250519T1 (hr) Supstituirani aminotiazoli kao inhibitori dgkzeta za imunološku aktivaciju
JP2007519754A5 (enExample)
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
CN104781254B (zh) 可作为激酶调节剂的经杂芳基取代的吡啶基化合物
RU2388750C2 (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
CN107074867B (zh) 作为jak抑制剂的氨基嘧啶基化合物
RU2338742C2 (ru) Производные индола, способ их получения (варианты), промежуточные соединения, используемые для их получения, фармацевтическая композиция содержащая их и их применение для лечения состояний, связанных с гликоген-синтазой-киназой-3
CA2827072C (en) Diaminopyrimidine derivatives and processes for the preparation thereof
RU2004112770A (ru) Производные имидазол-4-карбоксамида, их получение и применение для лечения ожирения
JP6986065B2 (ja) 医薬化合物
JP2019537571A5 (enExample)
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2015122414A (ru) Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2017500364A5 (enExample)
JP2005504100A5 (enExample)
CA2732806A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2522435A1 (en) Inhibitors of akt activity
RU2005136655A (ru) Производные пиримидина, пригодные для лечения болезней, опосредованных сrth2
JP2016519156A5 (enExample)
JP2012501313A5 (enExample)
JP2016523911A5 (enExample)
JP2008501675A5 (enExample)
HRP20100284T1 (hr) Derivati piperazinila korisni u liječenju bolesti posredovanih receptorom gpr38
JP2016534143A5 (enExample)